PRELUDE THERAPEUTICS INC Deferred Tax Assets, Net of Valuation Allowance
PRELUDE THERAPEUTICS INC (PRLD) had Deferred Tax Assets, Net of Valuation Allowance of $4.69 million as of 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsNet · last filed 2026-03-10
- 2025-12-31: Deferred Tax Assets, Net of Valuation Allowance $4.69M.
- 2024-12-31: Deferred Tax Assets, Net of Valuation Allowance $5.01M.
- 2023-12-31: Deferred Tax Assets, Net of Valuation Allowance $5.01M.
- 2022-12-31: Deferred Tax Assets, Net of Valuation Allowance $574.00K.
| Period end | Deferred Tax Assets, Net of Valuation Allowance |
|---|---|
| 2025-12-31 | $4.69M 10-K · filed 2026-03-10 |
| 2024-12-31 | $5.01M 10-K · filed 2026-03-10 |
| 2023-12-31 | $5.01M 10-K · filed 2025-03-10 |
| 2022-12-31 | $574.00K 10-K · filed 2024-02-15 |
| 2021-12-31 | $587.00K 10-K · filed 2023-03-15 |
| 2020-12-31 | $170.00K 10-K · filed 2022-03-17 |
| 2019-12-31 | $466.00K 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |